Developing Technologies to Transform Gastroenterology
ProTractX3 is an investigational device in the United States. Limited by federal law to clinical investigational use.
ProTractX3™ 3-Stage TTS DCB
(Drug Coated Balloon)
GIE Medical is a clinical stage company conducting trials in the US helping patients who suffer from benign stricture(s) of the:
• Bowel (small intestine, colon, and rectum)
GIE Medical’s Drug Coated Balloon could offer a new solution for treating GI strictures. Potentially creating sustained patency and reducing the number of treatments.
THE STRICTURE CYCLE
Dilation with rigid or balloon dilatators
30-40% of patients experience symptomatic recurrence within one year of successful dilation1
1 Said A, Brust DJ; Predictors of early recurrence of benign esophageal strictures; Am J Gastroenterology, 2003
If you are a patient 22 and older with benign stricture disease of the esophagus or large and small bowel and would like to be considered for the clinical study, click here.
Lixiao Wang, PhD
Founder and Chief Executive Officer
Lutonix Co-Founder/CTO and Urotronic Founder/CTO Prior experience includes: Lutonix, Urotronic, Boston Scientific, and EV3
Chief Operating Officer
Prior experience includes: Urotronic, Spectranetics, Covidien, EV3, and SurModics
VP of Operations and Quality
Prior experience includes: Philips, Lutonix, SurModics
Chief Financial Officer
Prior experience includes: BHI, Rotation Medical and Tendyne
Sew-Wah Tay, PhD
VP of Clinical and Regulatory
Prior experience includes: Boston Scientific, AMS and Libra Medical
VP of Clinical Affairs
Prior experience includes: Urotronic, NAMSA, Lutonix
Vice President Market Development
Prior experience includes:
Medtronic, Boston Scientific
GIE Medical Announces First Patient Enrolled in PATENT-E Benign Esophageal Stricture Treatment Study
The large, multicenter randomized controlled clinical trial is evaluating the safety and efficacy of the ProTractX3™ TTS drug coated balloon for the treatment of benign esophageal strictures
MINNEAPOLIS - Dec. 8, 2023 - GIE Medical, a clinical stage company developing solutions for patients suffering from benign stricture(s) of the esophagus or bowel, announced today that enrollment has begun in its Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture - Esophagus (PATENT-E) study. The study is evaluating the safety and efficacy of the first of its kind ProTractX3™ TTS drug coated balloon (DCB) and the first patient was enrolled at the University of North Carolina School of Medicine.
“We are excited to be testing this promising new technology,” said Nicholas J. Shaheen, MD, MPH, Chief, Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine. “Our patients with difficult-to-treat strictures need treatment options that are effective and safe. We hope to show that this innovative approach provides a new direction for them.”
For any inquiries or questions, please fill out the following form.
GIE Medical, Inc.
7601 Northland Drive, Suite 170,
Brooklyn Park, MN 55428 USA